A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis - Concepedia

Concepedia

Publication | Closed Access

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis

24

Citations

29

References

2016

Year

R.J. Arceci, Carl E. Allen, Ira J. Dunkel, Eric D. Jacobsen, James A. Whitlock, Robert Vassallo, Shannon R. Morris, Alison Portnoy, Beth Ann Reedy, Deborah A. Smith,

Pediatric Blood & Cancer

Abstract

Afuresertib has clinical activity in some patients with newly diagnosed and advanced LCH.

References

	Year	Citations

Page 1